FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma By Ogkologos - February 21, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHO study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant... September 19, 2024 ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC November 23, 2021 Grace and Love for Full Hands March 31, 2021 FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... March 27, 2025 Load more HOT NEWS Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... ESMO Congress 2022, 9-13 September
